Joseph Shulman - 09 Feb 2024 Form 4/A - Amendment Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: Chief Technical Officer
Signature: /s/ Stephen Vander Stoep as Attorney-in-Fact for Joseph Shulman
Issuer symbol: RYTM
Transactions as of: 09 Feb 2024
Net transactions value: +$1,420,540
Form type: 4/A - Amendment
Filing time: 13 Nov 2024, 21:01:54 UTC
Date Of Original Report: 13 Feb 2024
Previous filing: 05 Feb 2024
Next filing: 15 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Options Exercise	$1,393,442	+65,175	+1244%	$21.38	70,415	09 Feb 2024	Direct	F1
transaction	RYTM	Common Stock	Options Exercise	$27,098	+3,985	+5.7%	$6.80	74,430	09 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Stock Option (right to buy)	Options Exercise	$0	-65,175	-86%	$0.000000	10,625	09 Feb 2024	Common Stock	65,175	$21.38	Direct	F1, F2
transaction	RYTM	Stock Option (right to buy)	Options Exercise	$0	-3,985	-11%	$0.000000	31,875	09 Feb 2024	Common Stock	3,985	$6.80	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised.
F2	The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F3	The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Remarks:

Exhibit 24